What is the 13F Pro Quality Score for LNSR?

13F Pro ranks LENSAR, Inc. (LNSR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LNSR's current score at https://13fpro.ai/research/LNSR (free sign-up required for the full ranking).

Where does 13F Pro source LNSR data?

All LENSAR, Inc. fundamentals and ownership data come directly from SEC EDGAR. LENSAR, Inc. files with the SEC under CIK 1320350. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LNSR in?

LENSAR, Inc. (LNSR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LNSR research updated on 13F Pro?

LNSR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LENSAR, Inc.(LNSR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1320350 LNSR stock profile & AI dashboard →

13F Pro Quality Score

50.7/100

Rank #1,440 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.1/100

Profitability

72.2/100

Balance Sheet

69.8/100

Earnings Quality

30.0/100

Free Cash Flow

10.3/100

Institutional Flow

73.6/100

Revenue Scale

10.7/100

Dilution Risk

24.9/100

LNSR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LENSAR, Inc. (LNSR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LNSR at 50.7/100 on a 32-signal composite quality model, placing it at rank #1,440 of 2,879 stocks — the bottom half of the AI-ranked universe. LNSR scores in the top quartile across revenue growth (81.1). Areas of concern include free cash flow (10.3) and revenue scale (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LENSAR, Inc. reports quarterly revenue of $13.4M, net income of $36.3M, free cash flow of $-4.3M. Top institutional holders of LNSR by reported 13-F value include BRANDES INVESTMENT PARTNERS,, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LNSR trades on the Nasdaq exchange and files with the SEC under CIK 1320350. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNSR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LENSAR, Inc. directly from SEC EDGAR. LENSAR, Inc.'s 13F Pro composite quality score has ranged between 17 and 51 since 2022, currently 50.7 — an improving long-term trajectory across 26 quarterly and live scoring snapshots.

✦

Fun facts about LENSAR, Inc.

Quirks, history, and lore behind LNSR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is a niche specialist, not a sprawling healthcare giant, with a market cap well under $200 million.
3
The History
The company was spun out of Pfizer and has focused its entire existence on a single surgical subspecialty: eye surgery.
4
The Secret
Its core technology uses a femtosecond laser to automate the most delicate steps of cataract surgery, replacing the traditional manual blade with sub-micron precision.
5
The Lore
Its laser system integrates 3D imaging and artificial intelligence to guide the surgeon in real time — essentially turning a routine eye procedure into a robotic operation.
6
The Giveaway
The name is literally a mashup of "lens" and "laser" — because that is exactly, and only, what this Orlando company does to your cataracts.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$13.4M

Net Income

Q1 2026

$36.3M

Free Cash Flow

Q1 2026

$-4.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.2% YoY

$58.4MFY 2025

FY22 $35.4MFY23 $42.2MFY24 $53.5MFY25 $58.4M

Net Income

-9.2% YoY

$-34.3MFY 2025

FY22 $-19.9MFY23 $-14.4MFY24 $-31.4MFY25 $-34.3M

Operating Income

-130.5% YoY

$-24.6MFY 2025

FY22 $-20.2MFY23 $-12.2MFY24 $-10.7MFY25 $-24.6M

EPS (Diluted)

-5.1% YoY

$-2.87FY 2025

FY22 $-1.96FY23 $-1.31FY24 $-2.73FY25 $-2.87

Total Assets

+7.7% YoY

$71.4MFY 2025

FY22 $55.8MFY23 $69.6MFY24 $66.3MFY25 $71.4M

Op. Cash Flow

-551.9% YoY

$-14.8MFY 2025

FY22 $-14.9MFY23 $-9.7MFY24 $-2.3MFY25 $-14.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$58.4M +9.2%	$53.5M +26.9%	$42.2M +19.2%	$35.4M +34.0%	$26.4M -13.6%	$30.5M
Net Income	$-34.3M -9.2%	$-31.4M -118.3%	$-14.4M +27.8%	$-19.9M -0.7%	$-19.8M -34.9%	$-14.7M
Operating Income	$-24.6M -130.5%	$-10.7M +12.8%	$-12.2M +39.4%	$-20.2M -9.1%	$-18.5M -45.5%	$-12.7M
EPS (Diluted)	$-2.87 -5.1%	$-2.73 -108.4%	$-1.31 +33.2%	$-1.96	—	—
Total Assets	$71.4M +7.7%	$66.3M -4.7%	$69.6M +24.6%	$55.8M -29.4%	$79.1M +129.1%	$34.5M
Operating Cash Flow	$-14.8M -551.9%	$-2.3M +76.4%	$-9.7M +35.0%	$-14.9M -7.7%	$-13.8M -9.5%	$-12.6M

Get alerted when LNSR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LENSAR, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LNSR

BRANDES INVESTMENT PARTNERS, LP
$6.1M1,025,176 sh
BlackRock, Inc.
$3.7M628,748 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.3M390,090 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4M229,740 sh
DIMENSIONAL FUND ADVISORS LP
$1.3M224,934 sh
Groupe la Francaise
$1.3M213,537 sh
CSS LLC/IL
$974.2K163,450 sh
CREDIT INDUSTRIEL ET COMMERCIAL
$860.4K144,359 sh
Kerrisdale Advisers, LLC
$830.8K139,390 sh
STATE STREET CORP
$809.0K135,740 sh

Fund	Value	Shares
BRANDES INVESTMENT PARTNERS, LP	$6.1M	1,025,176
BlackRock, Inc.	$3.7M	628,748
VANGUARD CAPITAL MANAGEMENT LLC	$2.3M	390,090
GEODE CAPITAL MANAGEMENT, LLC	$1.4M	229,740
DIMENSIONAL FUND ADVISORS LP	$1.3M	224,934
Groupe la Francaise	$1.3M	213,537
CSS LLC/IL	$974.2K	163,450
CREDIT INDUSTRIEL ET COMMERCIAL	$860.4K	144,359
Kerrisdale Advisers, LLC	$830.8K	139,390
STATE STREET CORP	$809.0K	135,740

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LNSR on your watchlist

Track score changes the day LENSAR, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LNSR a good stock to buy?

13F Pro's AI-powered analysis of LENSAR, Inc. (LNSR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LNSR are available on the LNSR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LNSR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LNSR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LENSAR, Inc.'s investment landscape.